<p>阿尔忒弥斯投资管理有限公司在第四季度购买了百时美施贵宝公司（NYSE:BMY - 免费报告）的新股份，根据其最近向证券交易委员会提交的 13F 文件。该基金购买了 1,740,753 股该生物制药公司的股票，价值约为 93,896,000 美元。百时美施贵宝大约占阿尔忒弥斯投资管理有限公司投资组合的 1.1%，成为其第 25 大持股。阿尔忒弥斯投资管理有限公司在最近一个季度末持有百时美施贵宝约 0.09% 的股份。</p>
<p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
<ul>
<li>2 只巴菲特股票值得重仓——1 只需抛弃</li>
</ul>
<p>其他一些机构投资者也对该公司的持股进行了调整。达尔文财富管理有限公司在第二季度以约 25,000 美元的价格收购了百时美施贵宝的股份。医师财富顾问公司在第四季度将其在百时美施贵宝的持股增加了 73.5%。医师财富顾问公司现在拥有 477 股该生物制药公司的股票，价值 26,000 美元，此前在上个季度又购买了 202 股。EQ 财富顾问有限公司在第四季度以约 32,000 美元的价格收购了百时美施贵宝的股份。KERR 财务规划公司在第三季度以约 35,000 美元的价格收购了百时美施贵宝的股份。最后，JPL 财富管理有限公司在第三季度以约 36,000 美元的价格收购了百时美施贵宝的股份。机构投资者持有该公司 76.41% 的股票。</p>
<h2>分析师评级变动</h2>
<p>BMY 已成为多份研究分析师报告的主题。加拿大皇家银行在 2 月 24 日的研究报告中开始覆盖百时美施贵宝的股票。他们给予该股 “行业表现” 评级，并设定 60.00 美元的目标价。汇丰银行在 3 月 17 日的研究报告中将百时美施贵宝的目标价从 53.00 美元上调至 60.00 美元，并给予该股 “持有” 评级。Leerink Partners 在 1 月 13 日的研究报告中将百时美施贵宝的目标价从 54.00 美元上调至 60.00 美元，并给予该股 “跑赢大盘” 评级。富国银行在 2 月 6 日的研究报告中重申了 “跑赢大盘” 评级，并将百时美施贵宝的目标价设定为 60.00 美元（上调自 55.00 美元）。最后，摩根士丹利在 2 月 6 日的研究报告中重申了 “减持” 评级，并将百时美施贵宝的目标价设定为 40.00 美元。八位研究分析师对该股给予了买入评级，十位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股的平均评级为 “持有”，共识目标价为 61.31 美元。</p>
<ul>
<li>为什么 GRAIL 股票可能成为生物技术的下一个重大突破</li>
</ul>
<p><strong>查看我们关于百时美施贵宝的最新研究报告</strong></p>
<h2>百时美施贵宝的内部活动</h2>
<p>在其他新闻中，执行副总裁 David V. Elkins 在 4 月 1 日的交易中出售了 30,000 股公司的股票。股票以平均价格 61.67 美元出售，总价值为 1,850,100.00 美元。出售后，该执行副总裁直接持有 159,248 股公司的股票，价值约为 9,820,824.16 美元。这代表其持股减少了 15.85%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。公司内部人士持有该公司 0.05% 的股票。</p>
<h2>百时美施贵宝的关键新闻</h2>
<ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
<p>以下是本周影响百时美施贵宝的关键新闻：</p>
<ul>
<li>积极情绪：BMY 发布了第一季度业绩超出预期——每股收益 1.58 美元，市场共识约为 1.42 美元，收入为 114.9 亿美元——得益于增长药物和 Eliquis 的超预期表现，支持近期现金流。百时美施贵宝在血液稀释剂和癌症销售上发布了高于预期的季度利润</li>
<li>积极情绪：管理层重申了财年的展望，并强调 “增长组合”（Breyanzi，Camzyos）和成本削减进展是推动持久利润率改善的因素。百时美施贵宝在第一季度电话会议后发出信心信号</li>
<li>积极情绪：管道催化剂可能提升长期增长：milvexian（潜在的 Eliquis 接班人）和 Cobenfy（精神分裂症）的三期结果被强调为多年的驱动因素。BMS 在第一季度的平淡表现中带来了对晚期结果的关注</li>
<li>中性情绪：分析师的共识目标价接近 61.31 美元，表明在缺乏新的积极催化剂的情况下，当前水平的上涨空间有限。百时美施贵宝公司 NYSE: BMY 收到分析师的 61.31 美元共识目标价</li>
<li>消极情绪：2026 财年指引（每股收益 6.05–6.35；收入 460–475 亿美元）使收入中点略低于市场预期，抑制了季度后的上涨空间，并导致获利回吐。百时美施贵宝发布 2026 年第一季度财务业绩</li>
<li>消极情绪：分析师/覆盖报告强调了 Eliquis 专利悬崖的规模（未来几年数十亿美元的风险），这对估值施加了压力，超出近期的超预期表现。收入下降：Eliquis 专利悬崖的内部情况</li>
<li>消极情绪：伯恩斯坦维持持有评级，表明一些投资者和分析师希望看到更明确的证据，证明增长和管道将抵消传统业务的下降。伯恩斯坦对百时美施贵宝（BMY）维持持有评级</li>
</ul>
<h2>百时美施贵宝股价下跌 3.9%</h2>
<p>BMY 股票在周五开盘价为 58.24 美元。百时美施贵宝公司的 12 个月低点为 42.52 美元，12 个月高点为 62.89 美元。该公司的速动比率为 1.14，流动比率为 1.26，债务股本比率为 2.32。该公司的市值为 1189.2 亿美元，市盈率为 16.88，市盈增长比率为 0.17，贝塔值为 0.26。该股票的 50 天简单移动平均线为 59.56 美元，200 天简单移动平均线为 54.48 美元。</p>
<p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近一次发布财报是在 4 月 30 日星期四。这家生物制药公司报告本季度每股收益为 1.58 美元，超出分析师一致预期的 1.42 美元，超出幅度为 0.16 美元。百时美施贵宝的净利润率为 15.01%，股本回报率为 66.57%。该公司本季度的收入为 114.9 亿美元，而分析师预期为 109.3 亿美元。去年同期，该公司每股收益为 1.80 美元。本季度的收入较去年同期增长了 2.6%。百时美施贵宝已将其 2026 财年的指导目标设定为每股收益 6.050-6.350 美元。整体来看，卖方分析师预测百时美施贵宝公司在当前财年将发布每股收益 6.27 美元。</p>
<h2>百时美施贵宝分红公告</h2>
<p>该公司最近还披露了季度分红，已于 5 月 1 日星期五支付。4 月 2 日星期四的股东获得了 0.63 美元的分红。这相当于年化 2.52 美元的分红和 4.3% 的分红收益率。该分红的除息日为 4 月 2 日星期四。百时美施贵宝的分红支付比率目前为 73.04%。</p>
<h2>百时美施贵宝简介</h2>
<p>（免费报告）</p>
<p>百时美施贵宝是一家总部位于新泽西州普林斯顿的全球生物制药公司，专注于发现、开发和提供针对严重疾病的药物。公司的核心业务包括研究与开发、临床开发、制造和商业化多个治疗领域的处方药。BMS 专注于通过小分子和生物制剂推进肿瘤学、血液学、免疫学、心血管疾病和特殊领域的治疗。</p>
<p>BMS 的市场产品组合和后期管线反映了对癌症和免疫介导疾病的强烈关注。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比百时美施贵宝更好的股票</li>
</ul>
<p><strong>想知道其他对 BMY 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取百时美施贵宝公司（NYSE:BMY - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在百时美施贵宝吗？</h2>
<p>在考虑百时美施贵宝之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而百时美施贵宝并不在名单上。</p>
<p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

百时美施贵宝

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

<p>阿尔忒弥斯投资管理有限公司在百时美施贵宝公司（NYSE:BMY）中获得了新的股份，在第四季度购买了 1,740,753 股，价值约为 9390 万美元。这项投资占阿尔忒弥斯投资组合的约 1.1%，使 BMY 成为其第 25 大持股。其他机构投资者也增加了对该公司的持股。分析师对 BMY 的评级褒贬不一，普遍目标价为 61.31 美元。近期的积极财报和增长前景受到关注，尽管一些分析师对未来的上涨表示谨慎</p>

<p>Artemis Investment Management LLP purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The fund purchased 1,740,753 shares of the biopharmaceutical company's stock, valued at approximately $93,896,000. Bristol Myers Squibb makes up approximately 1.1% of Artemis Investment Management LLP's investment portfolio, making the stock its 25th largest holding. Artemis Investment Management LLP owned approximately 0.09% of Bristol Myers Squibb at the end of the most recent quarter.</p>
<div class="lb-trans"><p>阿尔忒弥斯投资管理有限公司在第四季度购买了百时美施贵宝公司（NYSE:BMY - 免费报告）的新股份，根据其最近向证券交易委员会提交的 13F 文件。该基金购买了 1,740,753 股该生物制药公司的股票，价值约为 93,896,000 美元。百时美施贵宝大约占阿尔忒弥斯投资管理有限公司投资组合的 1.1%，成为其第 25 大持股。阿尔忒弥斯投资管理有限公司在最近一个季度末持有百时美施贵宝约 0.09% 的股份。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
</div><ul>
<li>2 Buffett Stocks to Load Up On—And 1 to Ditch</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只巴菲特股票值得重仓——1 只需抛弃</li>
</ul>
</div><p>A number of other institutional investors have also made changes to their positions in the business. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Physician Wealth Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 202 shares during the last quarter. EQ Wealth Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $32,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Bristol Myers Squibb in the third quarter valued at approximately $35,000. Finally, JPL Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the third quarter valued at approximately $36,000. Institutional investors own 76.41% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者也对该公司的持股进行了调整。达尔文财富管理有限公司在第二季度以约 25,000 美元的价格收购了百时美施贵宝的股份。医师财富顾问公司在第四季度将其在百时美施贵宝的持股增加了 73.5%。医师财富顾问公司现在拥有 477 股该生物制药公司的股票，价值 26,000 美元，此前在上个季度又购买了 202 股。EQ 财富顾问有限公司在第四季度以约 32,000 美元的价格收购了百时美施贵宝的股份。KERR 财务规划公司在第三季度以约 35,000 美元的价格收购了百时美施贵宝的股份。最后，JPL 财富管理有限公司在第三季度以约 36,000 美元的价格收购了百时美施贵宝的股份。机构投资者持有该公司 76.41% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>BMY has been the topic of several research analyst reports. Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a &#34;sector perform&#34; rating and a $60.00 price objective on the stock. HSBC increased their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a &#34;hold&#34; rating in a research note on Tuesday, March 17th. Leerink Partners raised their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, January 13th. Wells Fargo &amp; Company reaffirmed an &#34;outperform&#34; rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Finally, Morgan Stanley restated an &#34;underweight&#34; rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of &#34;Hold&#34; and a consensus price target of $61.31.</p>
<div class="lb-trans"><p>BMY 已成为多份研究分析师报告的主题。加拿大皇家银行在 2 月 24 日的研究报告中开始覆盖百时美施贵宝的股票。他们给予该股 “行业表现” 评级，并设定 60.00 美元的目标价。汇丰银行在 3 月 17 日的研究报告中将百时美施贵宝的目标价从 53.00 美元上调至 60.00 美元，并给予该股 “持有” 评级。Leerink Partners 在 1 月 13 日的研究报告中将百时美施贵宝的目标价从 54.00 美元上调至 60.00 美元，并给予该股 “跑赢大盘” 评级。富国银行在 2 月 6 日的研究报告中重申了 “跑赢大盘” 评级，并将百时美施贵宝的目标价设定为 60.00 美元（上调自 55.00 美元）。最后，摩根士丹利在 2 月 6 日的研究报告中重申了 “减持” 评级，并将百时美施贵宝的目标价设定为 40.00 美元。八位研究分析师对该股给予了买入评级，十位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股的平均评级为 “持有”，共识目标价为 61.31 美元。</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 GRAIL 股票可能成为生物技术的下一个重大突破</li>
</ul>
</div><p><strong>View Our Latest Research Report on Bristol Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>查看我们关于百时美施贵宝的最新研究报告</strong></p>
</div><h2>Insider Activity at Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>百时美施贵宝的内部活动</h2>
</div><p>In other news, EVP David V. Elkins sold 30,000 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares of the company's stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.05% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 David V. Elkins 在 4 月 1 日的交易中出售了 30,000 股公司的股票。股票以平均价格 61.67 美元出售，总价值为 1,850,100.00 美元。出售后，该执行副总裁直接持有 159,248 股公司的股票，价值约为 9,820,824.16 美元。这代表其持股减少了 15.85%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。公司内部人士持有该公司 0.05% 的股票。</p>
</div><h2>Key Bristol Myers Squibb News</h2>
<div class="lb-trans"><h2>百时美施贵宝的关键新闻</h2>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
</div><p>Here are the key news stories impacting Bristol Myers Squibb this week:</p>
<div class="lb-trans"><p>以下是本周影响百时美施贵宝的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: BMY posted a Q1 beat — $1.58 EPS vs. consensus ~$1.42 and $11.49B revenue — driven by growth drugs and Eliquis outperformance, which supports near‑term cash flow. Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales</li>
<li>Positive Sentiment: Management reiterated FY outlook and emphasized the “growth portfolio” (Breyanzi, Camzyos) and cost‑cutting progress as drivers of durable margin improvement. Bristol-Myers Squibb Signals Confident Path After Q1 Call</li>
<li>Positive Sentiment: Pipeline catalysts could lift long‑term growth: Phase III readouts for milvexian (potential Eliquis successor) and Cobenfy (schizophrenia) are highlighted as multi‑year drivers. BMS brings the buzz around late-stage readouts amid a so-so Q1</li>
<li>Neutral Sentiment: Analysts’ consensus price target sits near $61.31, indicating limited upside from current levels absent new positive catalysts. Bristol Myers Squibb Company NYSE: BMY Receives $61.31 Consensus PT from Analysts</li>
<li>Negative Sentiment: FY 2026 guidance (EPS 6.05–6.35; revenue $46.0–47.5B) left the revenue midpoint slightly below the Street, tempering upside after the quarter and contributing to profit‑taking. Bristol Myers Squibb Reports First Quarter Financial Results for 2026</li>
<li>Negative Sentiment: Analysts/coverage notes emphasize the scale of the Eliquis patent cliff (multi‑billion dollar risk over coming years), which pressures valuation beyond near‑term beats. Thinning revenues: inside the $14bn Eliquis patent cliff</li>
<li>Negative Sentiment: Bernstein maintained a Hold rating, signaling that some investors and analysts want clearer evidence that growth and pipeline will offset legacy declines. Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：BMY 发布了第一季度业绩超出预期——每股收益 1.58 美元，市场共识约为 1.42 美元，收入为 114.9 亿美元——得益于增长药物和 Eliquis 的超预期表现，支持近期现金流。百时美施贵宝在血液稀释剂和癌症销售上发布了高于预期的季度利润</li>
<li>积极情绪：管理层重申了财年的展望，并强调 “增长组合”（Breyanzi，Camzyos）和成本削减进展是推动持久利润率改善的因素。百时美施贵宝在第一季度电话会议后发出信心信号</li>
<li>积极情绪：管道催化剂可能提升长期增长：milvexian（潜在的 Eliquis 接班人）和 Cobenfy（精神分裂症）的三期结果被强调为多年的驱动因素。BMS 在第一季度的平淡表现中带来了对晚期结果的关注</li>
<li>中性情绪：分析师的共识目标价接近 61.31 美元，表明在缺乏新的积极催化剂的情况下，当前水平的上涨空间有限。百时美施贵宝公司 NYSE: BMY 收到分析师的 61.31 美元共识目标价</li>
<li>消极情绪：2026 财年指引（每股收益 6.05–6.35；收入 460–475 亿美元）使收入中点略低于市场预期，抑制了季度后的上涨空间，并导致获利回吐。百时美施贵宝发布 2026 年第一季度财务业绩</li>
<li>消极情绪：分析师/覆盖报告强调了 Eliquis 专利悬崖的规模（未来几年数十亿美元的风险），这对估值施加了压力，超出近期的超预期表现。收入下降：Eliquis 专利悬崖的内部情况</li>
<li>消极情绪：伯恩斯坦维持持有评级，表明一些投资者和分析师希望看到更明确的证据，证明增长和管道将抵消传统业务的下降。伯恩斯坦对百时美施贵宝（BMY）维持持有评级</li>
</ul>
</div><h2>Bristol Myers Squibb Trading Down 3.9%</h2>
<div class="lb-trans"><h2>百时美施贵宝股价下跌 3.9%</h2>
</div><p>Shares of BMY stock opened at $58.24 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The firm has a market capitalization of $118.92 billion, a P/E ratio of 16.88, a P/E/G ratio of 0.17 and a beta of 0.26. The stock's fifty day simple moving average is $59.56 and its 200 day simple moving average is $54.48.</p>
<div class="lb-trans"><p>BMY 股票在周五开盘价为 58.24 美元。百时美施贵宝公司的 12 个月低点为 42.52 美元，12 个月高点为 62.89 美元。该公司的速动比率为 1.14，流动比率为 1.26，债务股本比率为 2.32。该公司的市值为 1189.2 亿美元，市盈率为 16.88，市盈增长比率为 0.17，贝塔值为 0.26。该股票的 50 天简单移动平均线为 59.56 美元，200 天简单移动平均线为 54.48 美元。</p>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts' consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 66.57%. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the firm posted $1.80 EPS. The company's revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.27 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近一次发布财报是在 4 月 30 日星期四。这家生物制药公司报告本季度每股收益为 1.58 美元，超出分析师一致预期的 1.42 美元，超出幅度为 0.16 美元。百时美施贵宝的净利润率为 15.01%，股本回报率为 66.57%。该公司本季度的收入为 114.9 亿美元，而分析师预期为 109.3 亿美元。去年同期，该公司每股收益为 1.80 美元。本季度的收入较去年同期增长了 2.6%。百时美施贵宝已将其 2026 财年的指导目标设定为每股收益 6.050-6.350 美元。整体来看，卖方分析师预测百时美施贵宝公司在当前财年将发布每股收益 6.27 美元。</p>
</div><h2>Bristol Myers Squibb Dividend Announcement</h2>
<div class="lb-trans"><h2>百时美施贵宝分红公告</h2>
</div><p>The company also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio is currently 73.04%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，已于 5 月 1 日星期五支付。4 月 2 日星期四的股东获得了 0.63 美元的分红。这相当于年化 2.52 美元的分红和 4.3% 的分红收益率。该分红的除息日为 4 月 2 日星期四。百时美施贵宝的分红支付比率目前为 73.04%。</p>
</div><h2>Bristol Myers Squibb Profile</h2>
<div class="lb-trans"><h2>百时美施贵宝简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.</p>
<div class="lb-trans"><p>百时美施贵宝是一家总部位于新泽西州普林斯顿的全球生物制药公司，专注于发现、开发和提供针对严重疾病的药物。公司的核心业务包括研究与开发、临床开发、制造和商业化多个治疗领域的处方药。BMS 专注于通过小分子和生物制剂推进肿瘤学、血液学、免疫学、心血管疾病和特殊领域的治疗。</p>
</div><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p>
<div class="lb-trans"><p>BMS 的市场产品组合和后期管线反映了对癌症和免疫介导疾病的强烈关注。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比百时美施贵宝更好的股票</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BMY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 BMY 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取百时美施贵宝公司（NYSE:BMY - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在百时美施贵宝吗？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑百时美施贵宝之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而百时美施贵宝并不在名单上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Artemis Investment Management LLP Takes Position in Bristol Myers Squibb Company $BMY

Market Beat

医疗业 ETF - SPDR

医药 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

美国制药 ETF - iShares

医疗业 ETF - Vanguard

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

2 倍做空卫生保健 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

Invesco Nasdaq Biotechnology ETF

标普生物技术 3 倍做多 - Direxion

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

Artemis Resources Limited

Apartment Investment

Artisan合伙资产管理

Nano Labs

Wealth Management Inc

WisdomTree国际非美国加拿大权益基金

WisdomTree汇率动态对冲国际股票ETF

Wealthfront

COtwo Advs Physical Eur Carb AllowanceTr

EQ HEALTH ACQUISITION CORP C/WTS 02/02/2028 (TO PUR COM)

卡尼金融储蓄

吉劳埃地产

Daishinku Corp.,

WealthNavi, Inc.

Jupiter Fund Management plc

加拿大皇家银行

蒙特利尔银行

加拿大帝国商业银行

汇丰

汇丰控股

汇丰控股有限公司

TRUE PARTNER

PC Partner

Ai Partners Financial Inc.

富国银行

摩根士丹利

GRAIL

Bristol-Myers Squibb Company

HSBC 5xShortSG241213

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Artemis Investment Management LLP 在百时美施贵宝公司（Bristol Myers Squibb）$BMY 中建立了头寸